Haak, H.R.

insulin cancer insulin glargine insulin analogues glargine diabetes study analogue participant model prescription type 2 diabetes breast cancer patient insulin prescription diabetologia number exposure breast analyses cohort comparison ogld use result analysis diagnosis cancer risk netherland type 1 diabetes table follow-up colon cancer pharmo latency time erasmus mc bladder cancer 1 january 1998 biguanide su latency 0.80 duration january period hospitalisation effect incidence time-dependent prostate cancer outcome 0.85 mellitu tract cancer calendar time malignancy association therapy adjustment disease 0.79 department author 0.89 body mass index prostate 0.76 incidence rate record bladder estimate colon meta-analysi contrast method medicine cancer diagnosis insulin therapy study cohort pharmo rls 0.75 regard